Ion Beam Applications SA
Charles Kumps has had extensive work experience in various industries and roles. Charles is currently a Board Member at N-SIDE since March 2022. Prior to that, they held multiple positions at IBA from 2017 onwards, including Chief Innovation and Development Officer, Executive Vice President Strategy, and Corporate Projects Director. Before joining IBA, they worked at McKinsey & Company as an Engagement Manager and Associate. Charles also worked at ING as a Structurer in Equity Derivatives and at ING Belgium as a Management trainee. Additionally, they were a Mathematic Modeler at Fortis.
Charles Kumps completed their Master's degree in Financial Management at Vlerick Business School from 2006 to 2007. Prior to that, they pursued a Bachelor's degree in Civil Engineering in Applied Mathematics at Université catholique de Louvain from 2000 to 2006.
This person is not in any teams
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.